Arvinas (NASDAQ:ARVN - Get Free Report) had its price objective lowered by stock analysts at Guggenheim from $57.00 to $32.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's target price indicates a potential upside of 270.50% from the stock's current price.
Other equities analysts also recently issued research reports about the company. Stifel Nicolaus cut their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. BMO Capital Markets set a $20.00 price target on Arvinas and gave the stock an "outperform" rating in a report on Wednesday. Wells Fargo & Company set a $26.00 price objective on Arvinas and gave the company an "overweight" rating in a research note on Wednesday. Barclays reduced their target price on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $81.00 price target on shares of Arvinas in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Arvinas presently has an average rating of "Moderate Buy" and a consensus target price of $39.29.
Check Out Our Latest Analysis on ARVN
Arvinas Price Performance
Shares of Arvinas stock traded down $0.39 during trading on Thursday, reaching $8.64. 2,070,118 shares of the company traded hands, compared to its average volume of 1,612,137. Arvinas has a 1-year low of $7.91 and a 1-year high of $46.23. The firm has a market capitalization of $593.98 million, a PE ratio of -3.08 and a beta of 1.95. The company has a 50 day moving average price of $17.77 and a 200-day moving average price of $22.11.
Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the firm earned ($2.53) earnings per share. Equities research analysts expect that Arvinas will post -3.81 earnings per share for the current year.
Insider Activity at Arvinas
In other Arvinas news, insider Ian Taylor sold 9,020 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Arvinas
Several institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in Arvinas in the fourth quarter worth approximately $28,000. KBC Group NV grew its holdings in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the last quarter. Quantbot Technologies LP raised its position in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Arvinas in the fourth quarter worth $171,000. Finally, Tema Etfs LLC purchased a new stake in Arvinas during the fourth quarter valued at about $227,000. 95.19% of the stock is currently owned by institutional investors.
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
